CureVac NV (WBO:CVAC) LT-Debt-to-Total-Asset : 0.05 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CureVac NV's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.05.

CureVac NV's long-term debt to total assets ratio increased from Mar. 2023 (0.04) to Mar. 2024 (0.05). It may suggest that CureVac NV is progressively becoming more dependent on debt to grow their business.

CureVac NV LT-Debt-to-Total-Asset Historical Data

The historical data trend for CureVac NV's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV LT-Debt-to-Total-Asset Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.59

0.02

0.04

0.05

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.04	0.04	0.05	0.05

CureVac NV LT-Debt-to-Total-Asset Calculation

CureVac NV's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	36.819	/	788.249
	=	0.05

CureVac NV's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	35.553	/	690.433
	=	0.05

CureVac NV (WBO:CVAC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CureVac NV LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CureVac NV's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.